Wsrtjtyk

European Medicines Agency

Agency overview
Formed	1 January 1995; 24 years ago (1995-01-01)
Jurisdiction	European Union
Headquarters	Amsterdam, Netherlands
Motto	Science. Medicines. Health.
Agency executives	Guido Rasi, Executive Director Christa Wirthumer-Hoche, Chairperson
Key document	Regulation (EC) No. 726/2004
Website	www.ema.europa.eu
Map
London European Medicines Agency (European Union)

European Union
This article is part of a series on the politics and government of the European Union
Member States Austria Belgium Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Gibraltar Presidency of the Council of the European Union Austria (July - December 2018) Special member state territories EU 3 Withdrawal from the European Union UK invocation of Article 50 Brexit
Treaties The Treaties Treaty of Paris (1951) Treaty of Rome (1957) Euratom Treaty (1957) Merger Treaty (1965) Single European Act (1986) Maastricht Treaty (1992) Amsterdam Treaty (1997) Treaty of Nice (2001) Treaty of Lisbon (2007) Article 7 Article 50 Opt-outs Treaties of Accession 1972, 1979, 1985, 1994, 2003, 2005, 2011 Other Treaties Schengen Agreement (1985) EEA Agreement (1992) Abandoned treaties and agreements European Constitution (2004) UK renegotiation of EU membership (2015-16)
Executive European Council President Tusk (EPP) Parties List of meetings European Commission Juncker Commission President Juncker (EPP) Vice Presidents College Civil Service Secretary-General Selmayr
Legislature European Parliament (Members) President Tajani (EPP) Largest groups EPP (Manfred Weber) S&D (Gianni Pittella) Member of the European Parliament 8th session (2014–19) Bureau Vice Presidents Quaestor Conference Legislative procedure Council of the EU (Presidency) Configurations General Foreign Justice and Home Economic Euro Legislative procedure Voting Secretariat Secretary-General Uwe Corsepius Directorates-general COREPER
Judiciary European Court of Justice Members Rulings General Court
Euro Eurozone Members Austria Belgium Cyprus Estonia Finland France Germany Greece Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Portugal Slovakia Slovenia Spain Eurogroup President Mário Centeno European Central Bank President Draghi ESCB EMU
Schengen Area Participating Schengen Area States Austria Belgium Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland (non-EU state) Italy Latvia Liechtenstein (non-EU state) Lithuania Luxembourg Malta Netherlands Norway (non-EU state) Poland Portugal Slovakia Slovenia Spain Sweden Switzerland (non-EU state) Prüm Convention Schengen Information System Visa Information System Visa policy of the Schengen Area
European Economic Area EEA Members Austria Belgium Bulgaria Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland (non-EU state) Ireland Italy Latvia Liechtenstein (non-EU state) Lithuania Luxembourg Malta Netherlands Norway (non-EU state) Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Gibraltar EEA Joint Committee EEA National Identity cards Microstates and the European Union
Court of Auditors Budget OLAF
Other Bodies European Atomic Energy Community Agencies Investment Bank CoR EESC Ombudsman National parliaments Former European Bodies European Communities (1958-1993) European Coal and Steel Community European Economic Community
Law Acquis Primacy Subsidiarity Regulation Directive Decision Fundamental Rights
Policies and Issues Budget Customs Union Four Freedoms Area of FS&J Policies Agricultural Energy Fisheries Regional Citizenship Passports of the European Union Identity Pro-Europeanism Euroscepticism Integration Supranationalism Federalism United States of Europe Enhanced co-op
Elections 1979, 1984, 1989 1994, 1999, 2004, 2009 2014 (last election) Political parties Constituencies Referendums
Other Unofficial EU Currencies Bulgarian lev Croatian kuna Czech koruna Danish krone Hungarian forint Polish złoty Romanian leu Swedish krona Pound sterling ERM II Enlargement of the Eurozone Bulgaria and the euro Croatia and the euro Czech Republic and the euro Denmark and the euro Hungary and the euro Poland and the euro Sweden and the euro Romania and the euro United Kingdom and the euro Black Wednesday Non-Schengen Area States Bulgaria Croatia Cyprus Ireland Romania United Kingdom Gibraltar Common Travel Area (UK & Ireland) Multi-speed Europe Candidate Countries for EU Membership Albania Bosnia and Herzegovina Macedonia Montenegro Serbia Turkey
Foreign Relations High Representative Federica Mogherini Foreign relations of EU Member States Austria Belgium Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Ext. Action Service Foreign Policy Defence Policy European Union Association Agreement Norway–European Union relations Switzerland–European Union relations United States-European Union relations European Union and the United Nations G7 G20
European Union portal Other countries Atlas
v t e

The European Medicines Agency (EMA) is a European Union agency for the evaluation of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).^[1][2]

The EMA was set up in 1995 with funding from the European Union and the pharmaceutical industry, as well as indirect subsidy from member states, in an attempt to harmonise (but not replace) the work of existing national medicine regulatory bodies. The hope was that this plan would not only reduce the €350 million annual cost drug companies incurred by having to win separate approvals from each member state but also that it would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies. The EU is currently the source of about one-third of the new drugs brought onto the world market each year.^{[citation needed]}

Based in London, the EMA was founded after more than seven years of negotiations among EU governments and replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, though both of these were reborn as the core scientific advisory committees. After the United Kingdom withdrawal from the European Union referendum the agency will relocate to Amsterdam.

Operations

The EMA operates as a decentralised scientific agency (as opposed to a regulatory authority) of the European Union and its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. More specifically, it coordinates the evaluation and monitoring of centrally authorised products and national referrals, develops technical guidance and provides scientific advice to sponsors. Its scope of operations is medicinal products for human and veterinary use including biologics and advanced therapies, and herbal medicinal products. The agency is composed of the Secretariat (ca. 600 staff), a management board, seven scientific committees (human, veterinary and herbal medicinal products, orphan drugs, paediatrics, advanced therapies and pharmacovigilance risk assessment) and a number of scientific working parties. The Secretariat is organised into five units: Directorate, Human Medicines Development and Evaluation, Patient Health Protection, Veterinary Medicines and Product Data Management, Information and Communications Technology and Administration. The Management Board provides administrative oversight to the Agency: including approval of budgets and plans, and selection of Executive Director. The Board includes one representative of each of the 28 Member States, two representatives of the European Commission, two representatives of the European Parliament, two representatives of patients' organisations, one representative of doctors' organisations and one representative of veterinarians' organisations. The Agency decentralises its scientific assessment of medicines by working through a network of about 4500 experts throughout the EU. The EMA draws on resources of over 40 National Competent Authorities (NCAs) of EU Member states.

Centralised marketing authorisations

The centralised procedure allows companies to submit a single application to the agency to obtain from the European Commission a centralised (or 'Community') marketing authorisation (MA) valid in all EU and European Economic Area (EEA)-European Free Trade Association (EFTA) states (Iceland, Liechtenstein and Norway). The centralised procedure is compulsory for all medicines derived from biotechnology and other high-tech processes, as well as for human medicines for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases, and for veterinary medicines for use for growth or yield enhancers. The centralised procedure is also open to products that bring a significant therapeutic, scientific or technical innovation, or is in any other respect in the interest of patient or animal health. As a result, the majority of genuinely novel medicines are authorised through the EMA.

For products eligible for or requiring centralised approval, a company submits an application for a marketing authorisation to the EMA.

Committees

Committee for Medicinal Products for Human Use

A single evaluation is carried out through the Committee for Medicinal Products for Human Use (CHMP). If the Committee concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. This is sent to the European Commission to be transformed into a marketing authorisation valid for the whole of the EU. A special type of approval is the paediatric-use marketing authorisation (PUMA), which can be granted for medical products intended exclusively for paediatric use.^[3]

The CHMP is obliged by the regulation to reach decisions within 210 days, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data.

Committee for Medicinal Products for Veterinary Use

The Committee for Medicinal Products for Veterinary Use (CVMP) operates in analogy to the CHMP as described above.

Committee on Orphan Medicinal Products

The Committee on Orphan Medicinal Products (COMP) administers the granting of orphan drug status since 2000. Companies intending to develop medicinal products for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than five in 10,000 persons in the European Union can apply for 'orphan medicinal product designation'. The COMP evaluates the application and makes a recommendation for the designation which is then granted by the European Commission.^{[citation needed]}

Committee on Herbal Medicinal Products

The Committee on Herbal Medicinal Products (HMPC) assists the harmonisation of procedures and provisions concerning herbal medicinal products laid down in EU Member States, and further integrating herbal medicinal products in the European regulatory framework since 2004.

Paediatric Committee

The Paediatric Committee (PDCO) deals with the implementation of the paediatric legislation in Europe Regulation(EC) No 1901/2006 since 2007. Under this legislation, all applications for marketing authorisation of new medicinal products, or variations to existing authorisations, have to either include data from paediatric studies previously agreed with the PDCO, or obtain a PDCO waiver or a deferral of these studies.

Committee for Advanced Therapies

The Committee for Advanced Therapies (CAT) was established in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) such as gene therapy, somatic cell therapy and tissue engineered products. It assesses the quality, safety and efficacy of ATMPs, and follows scientific developments in the field.

Pharmacovigilance Risk Assessment Committee

A seventh committee, the Pharmacovigilance Risk Assessment Committee (PRAC) has come into function in 2012 with the implementation of the new EU pharmacovigilance legislation (Directive 2010/84/EU).

Other activities

The Agency carries out a number of activities, including:

• 
  Pharmacovigilance: The Agency constantly monitors the safety of medicines through a pharmacovigilance network and EudraVigilance, so that it can take appropriate actions if adverse drug reaction reports suggest that the benefit-risk balance of a medicine has changed since it was authorised.


• 
  Referrals: The Agency coordinates arbitration procedures relating to medicinal products that are approved or under consideration by Member States in non-centralized authorisation procedures.


• 
  Scientific Advice: Companies wishing to receive scientific advice from the CHMP or CVMP on the appropriate tests and studies to carry out in the development of a medicinal products can request it prior to or during the development program.


• 
  Telematics projects: The Agency is responsible for implementing a central set of pan-European systems and databases such as EudraVigilance, EudraCT and EudraPharm.

Relocation

Following the 2016 decision of the United Kingdom to negotiate to leave the European Union ("Brexit"), the EMA chose to search for another base of operations. According to EU Law the European Commission had to decide on the fate of the EMA's location. The EU ministers met to vote on their preferred successor.^[4] The EU's Health Commissioner Vytenis Andriukaitis said that the preferred choice would be a location where an "easy set up and guarantee of smooth operations" would be available. Member states who had expressed their bid for the new EMA location were Austria,^[5]Belgium,^[6]Bulgaria,^[7]Croatia,^[5]Cyprus,^[5]Czech Republic,^[5]Denmark,^[5]Finland,^[8]France,^[5]Germany,^[5]Greece,^[5]Hungary,^[5]Ireland,^[5]Italy,^[5]Malta,^[5] the Netherlands,^[9]Poland,^[7]Portugal,^[10]Romania,^[11][12]Slovakia,^[5]Slovenia,^[5]Spain,^[5] and Sweden.^[13][14][15]

It had also been speculated that the Strasbourg-based seat for the European Parliament could be moved to Brussels, in exchange for the city to host the EMA.^[16] Others speculated on the merits of Amsterdam, well before the final decision was made.^[17][18]

The decision on the relocation was made on 20 November 2017 during the EU General Affairs Council meeting,^[19] after three voting rounds and finally drawing of lots. After the first round of voting, Milan (25 votes), Amsterdam (20 votes) and Copenhagen (20 votes) were the only contenders left.^[20] After the second voting round, two cities were left: Milan (twelve votes) and Amsterdam (nine votes). These two cities tied in the subsequent vote (thirteen votes each), after which a drawing of lots identified Amsterdam as the host city of EMA.

It is unclear what future arrangements the United Kingdom proposes to make for its own medicinal evaluation after leaving the EU. Paul Workman, the president of the London-based Institute of Cancer Research, has suggested that pharmaceutical companies would naturally seek regulatory approval for new drugs in the biggest markets first, leaving the UK facing delays in approval if they set up independent arrangements.^[21]

Criticism of the EMA process

The review process of the European Medicines Agency regarding medical issues has been criticized for its lack of transparency and issues of conflict of interest.^[22] In a rebuttal of an EMS review that included her work, Louise Brinth, a Danish physician, noted that "experts" reviewing data remain unnamed and seem to be bound to secrecy. Minutes are not released and diverging opinions are not reported suggesting that all the "experts" are of the same opinion. In her view the process is unscientific and undemocratic.^[23]

Comparison with other regulatory agencies

The EMA is roughly parallel to the drug part of the U.S. Food and Drug Administration (FDA),^[24] but without centralisation.^[25] The timetable for product approval via the EMA's centralised procedure of 210 days compares well with the average of 500 days taken by the FDA to evaluate a product.^[26]

See also

References

Further reading

• 
  McCormick, John (2004). The European Union: Politics and Policies. Boulder, Colo: Westview Press. ISBN 0-8133-4202-3.
  

External links

• Official website


• Heads of Medicines Agencies


• 
  The Rules Governing Medicinal Products in the European Union (EudraLex)


• 
  Health-EU Portal official public health portal of the European Union